'No More Drugs 1.2' campaign expands to Keningau, Tenom
Wong (centre) with No More Drugs 1.2 anti-drug campaign committee members.
KOTA KINABALU (June 27): Building on the momentum of a successful first wave earlier this year, Lions Clubs International District 308-A2 is launching the second phase of its anti-drug campaign, 'No More Drugs 1.2,' with a renewed focus on youth empowerment and intervention in high-risk communities across Sabah.
Earlier this year, 'No More Drugs 1.0' reached over 8,000 participants across Kota Kinabalu, Sandakan and Tawau. The campaign drew widespread engagement through personal testimonies, film screenings and youth forums that sparked heartfelt conversations about the dangers of substance abuse.
The upcoming phase will target Kota Kinabalu, Tenom, and notably Keningau — a district identified as a drug activity hotspot.
Organising chairperson Nelson Wong said the campaign is driven by the same spirit of unity and hope, with a goal to reach at least 6,000 people.
'This is more than just a campaign — it's a promise to our youth and to the future of Sabah,' said Wong.
'We are deeply committed to addressing the root causes of drug abuse, and we believe in empowering young people with the strength, awareness, and knowledge to choose a healthier, more meaningful path forward.'
The screening tour will begin on July 16 at St Michael's in Kota Kinabalu, before moving to Keningau the following day with visits to schools including SJK (C) Yuk Yin, SJK (C) Yuk Kong and SMJK Ken Hwa. A public screening will also be held that evening at SJK (C) Yuk Yin.
On July 18, the campaign will reach Tenom through a full-day programme involving several schools, such as SM Chung Hwa, SJK (C) Chung Hwa, and Tenom Tshung Tsin Secondary School. The tour concludes on July 19 with screenings at SM Tshung Tsin, Yue Min in Penampang, and Holy Seal at City Mall, Kota Kinabalu.
Beyond film screenings, the campaign will feature youth-focused forums, creative workshops and public engagement activities, supported by local authorities, schools and NGOs. Free counselling services and information on rehabilitation referrals will also be provided at each location.
The first phase was widely praised for its grassroots approach, drawing participation from students, teachers and civic leaders, while fostering honest conversations about substance abuse.
Lions Clubs International District 308-A2 also extended its gratitude to Second Vice District Governor-Elect Alyssa Lim, former organising chairlady, and her dedicated committee, whose leadership laid the foundation for the campaign's early success.
Like its predecessor, 'No More Drugs 1.2' reinforces the powerful message that when young people say no to drugs, they are saying yes to their dreams and to a brighter, healthier future.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Borneo Post
a day ago
- Borneo Post
'No More Drugs 1.2' campaign expands to Keningau, Tenom
Wong (centre) with No More Drugs 1.2 anti-drug campaign committee members. KOTA KINABALU (June 27): Building on the momentum of a successful first wave earlier this year, Lions Clubs International District 308-A2 is launching the second phase of its anti-drug campaign, 'No More Drugs 1.2,' with a renewed focus on youth empowerment and intervention in high-risk communities across Sabah. Earlier this year, 'No More Drugs 1.0' reached over 8,000 participants across Kota Kinabalu, Sandakan and Tawau. The campaign drew widespread engagement through personal testimonies, film screenings and youth forums that sparked heartfelt conversations about the dangers of substance abuse. The upcoming phase will target Kota Kinabalu, Tenom, and notably Keningau — a district identified as a drug activity hotspot. Organising chairperson Nelson Wong said the campaign is driven by the same spirit of unity and hope, with a goal to reach at least 6,000 people. 'This is more than just a campaign — it's a promise to our youth and to the future of Sabah,' said Wong. 'We are deeply committed to addressing the root causes of drug abuse, and we believe in empowering young people with the strength, awareness, and knowledge to choose a healthier, more meaningful path forward.' The screening tour will begin on July 16 at St Michael's in Kota Kinabalu, before moving to Keningau the following day with visits to schools including SJK (C) Yuk Yin, SJK (C) Yuk Kong and SMJK Ken Hwa. A public screening will also be held that evening at SJK (C) Yuk Yin. On July 18, the campaign will reach Tenom through a full-day programme involving several schools, such as SM Chung Hwa, SJK (C) Chung Hwa, and Tenom Tshung Tsin Secondary School. The tour concludes on July 19 with screenings at SM Tshung Tsin, Yue Min in Penampang, and Holy Seal at City Mall, Kota Kinabalu. Beyond film screenings, the campaign will feature youth-focused forums, creative workshops and public engagement activities, supported by local authorities, schools and NGOs. Free counselling services and information on rehabilitation referrals will also be provided at each location. The first phase was widely praised for its grassroots approach, drawing participation from students, teachers and civic leaders, while fostering honest conversations about substance abuse. Lions Clubs International District 308-A2 also extended its gratitude to Second Vice District Governor-Elect Alyssa Lim, former organising chairlady, and her dedicated committee, whose leadership laid the foundation for the campaign's early success. Like its predecessor, 'No More Drugs 1.2' reinforces the powerful message that when young people say no to drugs, they are saying yes to their dreams and to a brighter, healthier future.
Malaysian Reserve
16-06-2025
- Malaysian Reserve
C-Path's New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects
BRUSSELS and AMSTERDAM, June 16, 2025 /PRNewswire/ — The Innovative Health Initiative (IHI) and Critical Path Institute® (C-Path) today announced the publication of a peer-reviewed paper in Nature Reviews Drug Discovery, highlighting insights from multistakeholder global consortia launched over the past two decades to address barriers in drug development. Titled 'Delivering regulatory impact from consortium-based projects,' the paper presents a joint approach to addressing key challenges in developing tools to support regulatory decision-making. Drawing on the experience of cross-sector partnerships, the authors stress that collaboration alone is not enough to achieve meaningful impact on accelerating drug development. Key aspects to maximize regulatory impact include early regulatory engagement, clear evidentiary standards, and long-term planning for data access and sustainability. 'This work emphasizes the urgency—and feasibility—of building globally coordinated, cross-sector efforts to drive innovation for patients who have long been underserved,' said C-Path Vice President of Global Affairs Cécile Ollivier. 'By aligning stakeholders and lowering technical and regulatory barriers, we can reshape the drug development landscape.' As regulatory science becomes more central to translating innovation into patient benefit, the authors highlight the importance of taking a structured, strategic approach to regulatory issues, starting from the earliest stages of project planning and running right through to the post-project stage. 'We are collectively working to turn exciting advances in health research and innovation into real benefits for people and patients,' said Nathalie Seigneuret, Senior Scientific Project Manager at IHI. 'Regulatory science is key to making this happen, and we hope that this paper will help projects deliver results that meet regulators' needs.' Aligned with the IHI guide for applicants and project consortia on regulatory considerations for IMI and IHI projects, the paper outlines priorities for implementation: A clear regulatory strategy defined at project start A tailored data management plan aligned with regulatory goals A sustainability plan to ensure post-project data availability Early engagement with regulators led by experienced collaborators This paper reflects growing momentum for innovative and sustainable research whose results strive to accelerate medical product development and inform regulatory decision-making. Read the full paper, here, and supplementary material, here. About IHI The Innovative Health Initiative (IHI) aims to translate health research and innovation into real benefits for patients and society, and ensure that Europe remains at the cutting edge of interdisciplinary, sustainable, patient-centric health research. Health research and care increasingly involve diverse sectors. By supporting projects that bring these sectors together, IHI will pave the way for a more integrated approach to health care, covering prevention, diagnosis, treatment, and disease management. IHI is a partnership between the European Union and European industry associations representing the pharmaceutical, medical technology, biotechnology, digital health and vaccine industries, namely COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe. IHI's total budget is EUR 2.4 billion. Half of this comes from Horizon Europe, the EU's research and innovation programme. The IHI industry partners have committed EUR 1 billion to IHI, and a further EUR 200 million can be committed by other organisations that decide to become Contributing Partners. IHI builds on the successes of the Innovative Medicines Initiative (IMI), and the IHI Programme Office continues to manage the IMI project portfolio. For more information visit and follow IHI on LinkedIn, Bluesky and Mastodon. About Critical Path Institute Founded in 2005, as a public-private partnership in response to the FDA's Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit and follow C-Path on LinkedIn, X, Facebook, Instagram, BlueSky and YouTube. Media Contacts: Catherine BrettExternal Relations 2 541 8214 Roxan Triolo OlivasC-Path Communicationsrolivas@ 520-954-1634
The Star
12-06-2025
- The Star
Crumbling classrooms raise concern
Compiled by DIYANA PFORDTEN, C. ARUNO and R. ARAVINTHAN PUPILS of SJK(T) Ladang Kerling have been forced to attend classes sitting on the floor in a dingy room with a termite-damaged roof at a nearby national school, Malaysia Nanban reported. School board chairman M. Kumaran said the Public Works Department had stopped buses from using the road leading to the school as it is badly damaged. He said the Selangor education department allowed them to use rooms at a nearby school until the road was fixed, but no effort was made to prepare them. > Goa's chief minister had to step in after doctors threatened a strike over Health Minister Vishwajit Rane publicly scolding and threatening a doctor with suspension, Makkal Osai reported. A viral video of the incident sparked public backlash, prompting Vishwajit to apologise, saying he acted out of emotion. The Goa Association of Resident Doctors rejected the apology and warned of a strike unless a sincere one was made. Goa chief minister Pramod Sawant vowed to review the doctors' demands. The above articles are compiled from the vernacular newspapers (Bahasa Malaysia, Chinese and Tamil dailies). As such, stories are grouped according to the respective language/medium. Where a paragraph begins with a, it denotes a separate news item.
